Silo Pharma Gains European Patent for SPC-15 PTSD Therapy
SARASOTA, Fla., August 10, 2026 Silo Pharma, Inc. announced that the European Patent Office (EPO) has granted a patent...
Intranasal Therapy
Advertisement
Vistagen Reports Positive Phase 2 Fasedienol Repeat-Dose Data
SOUTH SAN FRANCISCO, Calif., August 6, 2026 Vistagen announced positive topline results from its exploratory Phase 2 repeat-dose clinical...
Silo Pharma Advances SPC-15 PTSD Program Toward FDA Meeting
SARASOTA, Fla., June 29, 2026 Silo Pharma announced that it has initiated a drug-device robustness study for SPC-15, its...
Nasus Pharma Reports Positive Preclinical Results for NS003
TEL AVIV, Israel, June 9, 2026 Nasus Pharma announced positive results from a preclinical pharmacokinetic (PK) and safety study...
Advertisement
